Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Research suggests relapses can lead to harm, reduce the quality of life, and have a heavy economic impact on patients with ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

Are family-based interventions effective and safe for people with schizophrenia and their families, compared with standard care?

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new, positive data on social ...

Most patients’ out-of-pocket costs will be much lower, depending on insurance and other factors. One cheaper generic called clozapine is widely considered one of the best treatments for schizophrenia, ...

Repeated miscommunications may hint at underlying mental health issues, affecting social cognition and relationships.

The most common are nausea ... One cheaper generic called clozapine is widely considered one of the best treatments for schizophrenia, Krystal said. It is underused in the U.S. compared to ...

Most people ... with schizophrenia only rarely seen in younger children. The usual age range of a schizophrenia diagnosis is 16 to 30 years old. It’s important to begin treatment for ...

This image provided by Bristol Myers Squibb in October 2024 shows the company's drug Cobenfy, which the U.S. Food and Drug Administration approved for the treatment of schizophrenia in September 2024.

Among this demographic, psychotic disorders alone contribute to 25 per cent of the total disease burden, with schizophrenia ...